SCHEMBL2080757

SCHEMBL2080757

Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.44
NR1H3 Q13133 8/20 0.43
NR1H2 P55055 7/20 0.43
TSHR P16473 4/20 0.43
CYP3A4 P08684 4/20 0.43
MAPK1 P28482 2/20 0.42
ALOX15 P16050 2/20 0.42
HSD17B10 Q99714 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 2/20 0.42
ESR2 Q92731 1/20 0.40
THRB P10828 1/20 0.40
HPGD P15428 1/20 0.40
CASP1 P29466 1/20 0.40
RECQL P46063 1/20 0.40
RORC P51449 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4609823 0.82 SMN1; SMN2 (0.48) ARSMN1; SMN2NR1H3NR1H2TSHR
SCHEMBL11601226 0.82 AR (0.54) ARNR1H3NR1H2TSHRMAPK1
SCHEMBL4598766 0.81 HSD11B1 (0.50) ARTSHRCYP3A4
SCHEMBL6691030 0.80 TSHR (0.46) ARSMN1; SMN2TSHRCYP3A4MAPK1
SCHEMBL9772291 0.80 TSHR (0.46) ARSMN1; SMN2TSHRCYP3A4MAPK1
SCHEMBL5958724 0.80 TSHR (0.46) ARSMN1; SMN2TSHRCYP3A4MAPK1
SCHEMBL119351 0.79 CYP3A4 (0.50) TSHRCYP3A4MAPK1ALOX15HSD17B10
SCHEMBL31053156 0.79 CYP3A4 (0.50) TSHRCYP3A4MAPK1ALOX15HSD17B10
SCHEMBL11371728 0.78 SMN1; SMN2 (0.46) ARSMN1; SMN2NR1H3NR1H2TSHR
SCHEMBL7101194 0.78 SMN1; SMN2 (0.55) ARSMN1; SMN2NR1H3NR1H2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240245633-A1 ROR Gamma Agonists as Enhancers of Protective Immunity UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2024-07-25 US disclosed
US-7897815-B2 Hexafluoroisopropanol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-03-01 US disclosed
US-20100004297-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES DEHMLOW HENRIETTA 2010-01-07 US disclosed
US-7608721-B2 Hexafluoroisopropanol derivatives HOFFMANN-LA ROCHE INC. (US) 2009-10-27 US disclosed
US-20080096937-A1 Novel hexafluoroisopropanol derivatives DEHMLOW HENRIETTA 2008-04-24 US disclosed
US-7300948-B2 Alkynyl compounds as non nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-11-27 US disclosed
US-20070213377-A1 Novel hexafluoroisopropanol derivatives DEHMLOW HENRIETTA 2007-09-13 US disclosed
US-7259178-B2 Containing an oxazole ring, e.g., 1,1,1,3,3,3-Hexafluoro-2-{4-[[5-methyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-(2,2,2-trifluoro-ethyl)-amino]-phenyl}-propan-2-ol; the compounds bind to and selectively activate LXR alpha and LXR beta; used to treat diseases such as atherosclerosis and diabetes HOFFMANN-LA ROCHE INC. (US) 2007-08-21 US disclosed
CN-1972897-A Novel hexafluoroisopropanol derivative HOFFMANN LA ROCHE (CH) 2007-05-30 CN disclosed
EP-1763502-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2007-03-21 EP disclosed
US-20060004068-A1 Novel hexafluoroisopropanol derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-01-05 US disclosed
WO-2006000323-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-01-05 WO disclosed
WO-2003106435-A1 FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF SANKYO COMPANY, LIMITED (JP) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213377-A1 Novel hexafluoroisopropanol derivatives NR1H3, NR1H2, NR1I2 AR 542/4885SMN1; SMN2 4516/4885NR1H3 1/4885
US-20240245633-A1 ROR Gamma Agonists as Enhancers of Protective Immunity RORC, RORB, RORA AR 669/4885SMN1; SMN2 3772/4885NR1H3 514/4885
US-20100004297-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES NR1H3, NR1H2, NR1I2 AR 542/4885SMN1; SMN2 4516/4885NR1H3 1/4885
US-20080096937-A1 Novel hexafluoroisopropanol derivatives NR1H3, NR1H2, NR1I2 AR 542/4885SMN1; SMN2 4516/4885NR1H3 1/4885
US-20060004068-A1 Novel hexafluoroisopropanol derivatives NR1H3, NR1H2, NR1I2 AR 542/4885SMN1; SMN2 4516/4885NR1H3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.